ArticleClinical cardiology2025
The Prognostic Value of Platelet-Albumin-Bilirubin Score in Patients Undergoing Transcatheter Aortic Valve Replacement.
Article in Clinical cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Prognostic Value of Platelet-Albumin-Bilirubin Score in Patients Undergoing Transcatheter Aortic Valve Replacement.Clinical cardiology · 2025Article
- Association between the platelet-albumin-bilirubin score and all-cause mortality in ICU-admitted heart failure patients: a retrospective cohort analysis and machine learning-based prognostic modeling.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTranscatheter aortic valve replacement (TAVR) has emerged as a well-established treatment option for patients with aortic valve stenosis and/or regurgitation. However, risk stratification in patients indicated for TAVR remains challenging. This study aimed to evaluate the predictive value of the platelet-albumin-bilirubin (PALBI) score on post-TAVR mortality.
methodsA total number of 812 patients with aortic stenosis and/or aortic regurgitation who underwent TAVR were consecutively enrolled in this study. PALBI score was calculated based on preoperative baseline bilirubin levels, albumin levels, and platelet counts. Patients were categorized into two groups according to the median PALBI score.
resultsThe median age of the study population at baseline was 74 (IQR: 69.00-80.00) years, and 58.6% were male. During the whole follow-up period, all-cause death was observed in 60 (7.4%) patients and 30 (3.7%) patients died due to cardiovascular events. According to multivariate analysis, a high PALBI score was independently associated with all-cause mortality (HR = 2.679, 95% CI: 1.456-4.930, p = 0.002) and cardiovascular mortality (HR = 2.785, 95% CI: 1.133-6.849, p = 0.026). ROC curve analysis showed a significant predictive value of the PALBI score for all-cause mortality (AUC = 0.633, 95% CI: 0.563-0.704, p = 0.001). Furthermore, the PALBI score strengthens the predictive value of the Society of Thoracic Surgeons (STS) score for all-cause death after TAVR (STS score vs. PALBI score + STS score: AUC: 0.742 vs. 0.768).
conclusionA high PALBI score was associated with increased all-cause and cardiovascular mortality in patients after TAVR. PALBI score can further enhance the predictive potential of STS score for all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.